rs1554695039
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000264.5(PTCH1):c.2062C>T(p.Gln688*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000264.5 stop_gained
Scores
Clinical Significance
Conservation
Publications
- basal cell nevus syndrome 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- holoprosencephaly 7Inheritance: AD Classification: DEFINITIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- holoprosencephalyInheritance: AD Classification: LIMITED Submitted by: Illumina
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Gorlin syndrome Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in PTCH1 are known to be pathogenic (PMID: 16301862, 16419085). This variant has been reported in an individual affected with nevoid basal cell carcinoma syndrome (PMID: 8981943, 22952776). ClinVar contains an entry for this variant (Variation ID: 45381). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln688*) in the PTCH1 gene. It is expected to result in an absent or disrupted protein product. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q688* pathogenic mutation (also known as c.2062C>T), located in coding exon 14 of the PTCH1 gene, results from a C to T substitution at nucleotide position 2062. This changes the amino acid from a glutamine to a stop codon within coding exon 14. This mutation was identified in one individual out of a cohort of 71 unrelated individuals with nevoid basal cell carcinoma syndrome (NBCCS) (Wicking C et al. Am J Hum Genet, 1997 Jan;60:21-6). This mutation was also identified in a patient with a history of keratocystic odontogenic tumor, >10 basal cell carcinomas, and bifid rib who had a daughter with polydactaly and bifid rib (Pastorino L et al. PLoS One, 2012 Aug;7:e43827). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at